CAM-PaC will provide an armamentarium of novel and validated therapeutic targets, compounds and predictive tools that are expected to improve survival and reduce suffering of PDAC patients.

Furthermore, CAM-PaC as an SME-targeted consortium includes four research-intensive biotechnologies SME that will be provided with the possibility to develop and expand their portfolios of methods, applications and assays in a clinically meaningful context where the need for patients is compelling. It is anticipated that CAM-PaC will improve the competitiveness of participating SME on the European and International market.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.